EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference

On September 19, 2023 EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, reported that the company will present the first-in-human results for EMB-02 as a poster display at the 2023 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress on October 23 (local time) (Press release, EpimAb Biotherapeutics, SEP 19, 2023, View Source [SID1234635261]). This poster will feature initial safety, efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) data from the EMB-02 Phase I dose escalation study in advanced solid tumors (NCT04618393). The presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Preliminary Phase I Results from a First-in-Human Study of EMB-02, a PD-1xLAG-3 Bispecific Antibody, in Patients (pts) with Advanced Solid Tumors

Presentation number: 1028P

EMB-02 is a bispecific antibody based on EpimAb’s proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) technology, which generates bispecific molecules with superior properties. The EMB-02 bispecific antibody targets two checkpoint proteins, PD-1 and LAG-3, and restores effector T cell function through robust inhibition and degradation of the target proteins in the tumor microenvironment. In addition, it has shown strong anti-tumor efficacy in in vivo tumor models resistant to standard anti-PD-1 monotherapies.

Dr. Chengbin Wu, Founder and CEO of EpimAb commented, "The ESMO (Free ESMO Whitepaper) Congress is one of the premier global oncology conferences and we look forward to sharing the detailed EMB-02 data with key stakeholders, including clinicians, researchers, patient advocates, and other health industry representatives, at this event."